Stockscreener 앱 받기
14.17
0.49%
-0.07
전일 마감가:
$14.24
열려 있는:
$14
하루 거래량:
182.71K
Relative Volume:
0.26
시가총액:
$408.98M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-2.8626
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+1.65%
1개월 성능:
+31.08%
6개월 성능:
+99.30%
1년 성능:
+66.12%
1일 변동 폭
$13.93
$14.46
1주일 범위
$13.63
$14.52
52주 변동 폭
$4.09
$15.34
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
14.17 | 411.00M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Can Enanta Pharmaceuticals Inc. (9EP) stock survive global slowdownJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Will Enanta Pharmaceuticals Inc. (9EP) stock extend growth storyEarnings Overview Report & Capital Efficiency Focused Strategies - Newser
Is Enanta Pharmaceuticals Inc. (9EP) stock nearing a technical breakout - Newser
Is Enanta Pharmaceuticals Inc. stock a top momentum playQuarterly Market Summary & Risk Controlled Daily Trade Plans - Newser
VP Or Surrenders 753 Of Enanta Pharmaceuticals Inc [ENTA] - TradingView
ENTA: RSV and immunology pipelines advance with key candidates and pivotal trials planned for 2026 - TradingView
Is Enanta Pharmaceuticals Inc. (9EP) stock a defensive play amid uncertainty - Newser
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener
Certain Common Stock of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Does Enanta Pharmaceuticals Inc. stock trade at a discount to peersTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Portfolio Recap: What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds2025 Winners & Losers & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Enanta Pharmaceuticals Inc Stock Analysis and ForecastMarket Capitalization Trends & Free Unmatched Market Performance - earlytimes.in
Enanta Pharmaceuticals, Inc. (ENTA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What margin trends mean for Enanta Pharmaceuticals Inc. stockEarnings Growth Summary & Low Risk Entry Point Tips - moha.gov.vn
Enanta Pharmaceuticals insider awarded RSUs and 12,925 stock options - Stock Titan
[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Enanta Pharmaceuticals Form 4 shows 110,000 CSO options grant - Stock Titan
ENTA insider awarded 310,000 stock options expiring in 2035 - Stock Titan
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt? - simplywall.st
TROUT HARRY R III Insider Trades - Nasdaq
Trading Systems Reacting to (ENTA) Volatility - news.stocktradersdaily.com
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade - sharewise.com
Enanta Pharmaceuticals, Inc. (ENTA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How Enanta Pharmaceuticals Inc. (9EP) stock trades after rate cutsMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
How strong is Enanta Pharmaceuticals Inc. stock revenue growth2025 Volatility Report & Smart Money Movement Alerts - newser.com
MSN Money - MSN
Will Enanta Pharmaceuticals Inc. (9EP) stock announce a stock splitJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
How Enanta Pharmaceuticals Inc. (9EP) stock trades under stagflationJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
What sentiment indicators say about Enanta Pharmaceuticals Inc. stock2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
[10-K] ENANTA PHARMACEUTICALS INC Files Annual Report | ENTA SEC FilingForm 10-K - Stock Titan
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development (ENTA) - Seeking Alpha
Is Enanta Pharmaceuticals Inc. stock ready for a breakoutWeekly Trend Recap & Stock Portfolio Risk Control - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attentionGap Down & Weekly Market Pulse Alerts - newser.com
How Enanta Pharmaceuticals Inc. stock compares to growth peers2025 Pullback Review & Verified Momentum Watchlists - newser.com
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):